Abstract

Placing in-vitro heteroresistance in the context of clinical results

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Does cefiderocol heteroresistance explain the discrepancy between the APEKS-NP and CREDIBLE-CR clinical trial results?
Jesse T Jacob ... David S Weiss
The Lancet Microbe | VOL. 2
Jesse T Jacob, et. al.Jesse T Jacob ... David S Weiss
28 Oct 2021
A tricompartmental model of lung oxygenation disruption to explain pulmonary and systemic pathology in severe COVID-19
Dennis Mcgonagle ... James F M Meaney
The Lancet Respiratory Medicine | VOL. 9
Dennis Mcgonagle, et. al.Dennis Mcgonagle ... James F M Meaney
14 May 2021
Pneumococcal Bacteremia: Lessons Learned, Yet More to Learn
Dennis G Maki
Mayo Clinic Proceedings | VOL. 79
Dennis G MakiDennis G Maki
01 May 2004
Diversity of Serotype Replacement After Pneumococcal Conjugate Vaccine Implementation in Europe
Emmanuelle Varon ... Laurence Caeymaex
The Journal of Pediatrics | VOL. 213
Emmanuelle Varon, et. al.Emmanuelle Varon ... Laurence Caeymaex
24 Sep 2019
View more papers

More From: The Lancet Infectious Diseases

Paper Title
Journal
Date
Author
Global action to improve access to tools for cholera
Timothy Jesudason
The Lancet Infectious Diseases | VOL. 24
Timothy JesudasonTimothy Jesudason
01 Jun 2024
Theresa Ochoa—staying on top of infectious diseases in Peru
Tony Kirby
The Lancet Infectious Diseases | VOL. 24
Tony KirbyTony Kirby
01 Jun 2024
Highlights of ESCMID Global 2024
Phoebe Hall
The Lancet Infectious Diseases | VOL. 24
Phoebe HallPhoebe Hall
01 Jun 2024
Research in brief
Priya Venkatesan
The Lancet Infectious Diseases | VOL. 24
Priya VenkatesanPriya Venkatesan
01 Jun 2024
View more papers